Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferumoxytol versus oral iron in pediatric dialysis-dependent chronic kidney disease with iron deficiency anemia
2010-019387-37Phase 3Suspended
- Sponsor
- AMAG Pharmaceuticals, Inc.
- Start
- Aug 2010
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ferumoxytol and ferrous sulfate in iron deficiency anemia (IDA) (3 arms), sponsored by AMAG Pharmaceuticals, Inc. Primary endpoint: Mean change in hemoglobin from baseline to Week 5. Started Aug 2010; status: suspended.
02
Drugs
ferumoxytolferrous sulfate
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on 2010-019387-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019387-37.